Truliant Consulting has announced the release of its latest white paper, AI and Automation in Pharmacovigilance: Transformative Trends and Future Outlook. Launched today, the paper results from an open survey aimed at pharmaceutical companies to gauge their implementation of artificial intelligence (AI) within their pharmacovigilance (PV) frameworks.

Ms. Qian, Co-Founder of Truliant Consulting and co-author of the white paper, shared insights from the survey, stating, “We reached out to contacts in the industry and gathered valuable information from 15 companies of varying sizes and ICSR annual volumes. Their responses helped us understand how companies are deploying AI and their perceptions of future possibilities”.

The white paper clarifies the distinctions between automation and AI while providing examples of the technology’s application in PV over the years. Co-author Mr. Khurana highlighted, “AI has become a prominent topic at PV conferences and meetings. However, we find that PV experts often lack an understanding of the various technologies that can automate PV processes. We provide examples of how simple rule-based automation can enhance efficiency and how different AI types can be utilized”.

The authors stress that the successful application of AI in PV necessitates collaboration among regulators, pharmaceutical companies, and service vendors. They also point out that AI enhances rather than replaces human expertise.

The white paper is available on the Truliant Consulting website.